Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study

被引：0
|
作者：
Hochmair, M. J. [1 ,2 ]
Morabito, A. [3 ]
Hao, D. [4 ]
Yang, C-T. [5 ]
Soo, R. [6 ]
Yang, J. C-H. [7 ]
Gucalp, R. [8 ]
Halmos, B. [8 ]
Wang, L. [9 ]
Golembesky, A. [10 ]
Maerten, A. [10 ]
Cufer, T. [11 ]
机构：
[1] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria
[2] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria
[3] Fdn G Pascale IRCCS, Ist Nazl Tumori, Thorac Med Oncol, Naples, Italy
[4] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[5] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan
[6] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore, Singapore
[7] Natl Taiwan Univ, Canc Ctr, Natl Taiwan Univ Hosp, Taipei, Taiwan
[8] Montefiore Albert Einstein Canc Ctr, Dept Oncol, New York, NY USA
[9] Boehringer Ingelheim Taiwan Ltd, Taipei, Taiwan
[10] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[11] Univ Ljubljana, Univ Clin Golnik, Ljubljana, Slovenia
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1532P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC
    Nieva, J.
    Griesinger, F.
    Kim, Y.
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Sawyer, W.
    Shenolikar, R.
    Shaw, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S616 - S617
  • [22] Real-world, first-line Osimertinib treatment in epidermal growth factor receptor mutation-positive (EGFRm) advanced NSCLC
    Griesinger, F.
    Nieva, J.
    Kim, Y. -H
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Sawyer, W.
    Shenolikar, R.
    Shaw, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 254 - 254
  • [23] Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US
    Li, Y.
    Appius, A.
    Pattipaka, T.
    Feyereislova, A.
    Cassidy, A.
    Ganti, A. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2216 - S2216
  • [24] Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)
    Halmos, Balazs
    Tan, Eng-Huat
    Soo, Ross A.
    Cadranel, Jacques
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward
    Melosky, Barbara
    Maerten, Angela
    Carcereny, Enric
    LUNG CANCER, 2019, 127 : 103 - 111
  • [25] UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations
    Miura, S.
    Hsia, T-C.
    Hung, J-Y.
    Jung, H. A.
    Shih, J-Y.
    Yang, T-Y.
    Park, C-K.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S776 - S777
  • [26] Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC harboring uncommon mutations
    Yang, J. C-H.
    Schuler, M.
    Popat, S.
    Miura, S.
    Heeke, S.
    Passaro, A.
    de Marinis, F.
    Park, K.
    Kim, E. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S860 - S861
  • [27] Real-World Data of Osimertinib in Patients with Metastatic EGFRm plus NSCLC who Progressed on First-Line EGFR TKIs
    Ma, J.
    Tan, S. H.
    Yin, D.
    Tran, A.
    Tan, D.
    Ang, M.
    Takano, A.
    Lim, K. H. T.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Tan, E.
    Lim, D. W.
    Ng, Q. S.
    Tan, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S628
  • [28] Post-Marketing Observational Study of Japanese Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC Treated with Daily Afatinib (Final Report)
    Yamamoto, N.
    Nukiwa, T.
    Nakanishi, Y.
    Gemma, A.
    Mizushima, M.
    Takayama, T.
    Kumazawa, J.
    Azuma, H.
    Tamura, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2213 - S2214
  • [29] Afatinib in the treatment of advanced NSCLC with EGFR mutation: An observational real-world study.
    Li, Yun
    Wang, Xiaohua
    Wang, Li
    Kou, Yingying
    Ma, Xianglei
    Feng, Ji Feng
    Xiao, Mingzhe
    Shi, Meiqi
    Tang, Yiqun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Characteristics of Real-World Study: Taking the Observational Study of Osimertinib in Patients with EGRF Mutation-Positive NSCLC as an Example
    Feng, Rui-hua
    Cheng, Jiu
    Guo, Min-jiang
    Jiang, Xiao-tong
    Zhang, Chi
    LI, Ya-zi
    LATIN AMERICAN JOURNAL OF PHARMACY, 2023, 42 (05): : 1034 - 1041
12345